Earnings call transcript: Helen of Troy Q4 2026 beats expectations, stock surges

Helen of Troy beat fiscal Q4 2026 expectations with EPS of $0.83 vs. $0.75 consensus and revenue of $470 million vs. $450.8 million, while shares jumped 25.39% pre-market to $24.79. The company also reported international sales growth of 5.4% and reduced the fiscal-year net operating income impact from tariffs to less than $30 million, though gross margin fell 400 bps to 44.6%. FY2027 guidance calls for revenue of $1.751 billion-$1.822 billion and EPS of $3.25-$3.75, but management remains cautious on tariffs, consumer softness, and supply-chain risks.

Analysis

The market is treating this as a clean earnings beat, but the more interesting signal is that the business appears to be transitioning from a pure tariff shock absorber into a selective reinvestment story. That matters because the first-order margin recovery is probably largely behind them; the next leg of equity upside depends on whether pricing, innovation, and channel mix can re-accelerate top-line enough to restore operating leverage. In other words, this is less a “cost fix” and more a test of whether management can defend share while spending more.

The near-term winner set extends beyond HELE. Retail partners with strong replenishment math and shelf discipline should benefit if price increases hold and inventory stays tight; the strongest read-through is to WMT and TGT, which can absorb price architecture changes faster than smaller peers and use them to widen assortment gaps. The hidden loser is any competitor still concentrated in China-sourced, tariff-exposed SKUs: HELE’s dual-sourcing push lowers its own risk, but it also compresses the window for less-scaled brands to pass through cost without losing velocity.

The main tail risk is timing, not direction. If freight, resin, or other input costs stay elevated for 1-2 quarters while consumer elasticity worsens, HELE’s back-half weighted path becomes fragile because the company is effectively spending into a still-soft demand tape. A second-order risk is that the current rally is forcing the stock into a sentiment overhang: when positioning gets crowded after a sharp gap-up, even modest guide skepticism can trigger a fast multiple reset.

Contrarianly, the bullish case is not that margins snap back quickly; it’s that the market may be underestimating how much tariff normalization and mix improvement can matter once pricing is fully embedded. The bigger question is whether consensus is still valuing HELE like a structurally impaired business rather than a partially repaired one with 20%+ free-cash-flow yield optics. That setup is attractive, but only if execution stays clean over the next 90 days and the stock stops trading on story momentum alone.

Key Decisions for Investors

• Long HELE for a 4-8 week tactical trade, but only on pullbacks after the gap-up; target a re-rating toward the mid-$20s if management credibility on pricing and sourcing holds. Stop if the stock loses the post-earnings breakout and re-enters the pre-print range.
• Buy HELE Jan-2027 call spreads to express upside from tariff normalization and inventory recovery with defined downside. Best structure: buy delta on the thesis, not the volatility spike after the earnings gap.
• Pair long HELE / short a tariff-exposed small-cap consumer durable or personal-care name with limited sourcing flexibility over the next 1-2 quarters. The edge is execution leverage: HELE has already done the hard part on pricing and supply-chain diversification.
• Add a modest long WMT vs short TGT trade if the thesis is that stronger vendors with pricing power win the shelf reset. WMT should better capture assortment migration and vendor negotiation leverage if promotional intensity stays high.
• Take profits into strength if HELE extends another 10-15% from current levels without a subsequent revision to FY27 estimates. The risk/reward worsens once the market starts pricing a full recovery before evidence of sustained POS improvement.